ALX Oncology Holdings Analyst Ratings
ALX Oncology Holdings Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/14/2023 | 16.96% | Stifel | $11 → $10 | Maintains | Buy |
10/11/2023 | 28.65% | Piper Sandler | $8 → $11 | Maintains | Overweight |
10/04/2023 | 215.79% | UBS | $29 → $27 | Maintains | Buy |
10/04/2023 | 169.01% | Cantor Fitzgerald | $18 → $23 | Maintains | Overweight |
10/03/2023 | 104.68% | HC Wainwright & Co. | $16 → $17.5 | Reiterates | Buy → Buy |
09/12/2023 | 110.53% | Cantor Fitzgerald | → $18 | Reiterates | Overweight → Overweight |
09/07/2023 | 110.53% | Cantor Fitzgerald | → $18 | Reinstates | Overweight → Overweight |
08/14/2023 | 110.53% | Cantor Fitzgerald | $22 → $18 | Maintains | Overweight |
08/11/2023 | 110.53% | Cantor Fitzgerald | $22 → $18 | Maintains | Overweight |
08/11/2023 | -6.43% | Piper Sandler | $48 → $8 | Maintains | Overweight |
08/11/2023 | 87.13% | HC Wainwright & Co. | $30 → $16 | Maintains | Buy |
07/24/2023 | 157.31% | Cantor Fitzgerald | → $22 | Reiterates | Overweight → Overweight |
05/12/2023 | 250.88% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
03/15/2023 | 239.18% | UBS | $31 → $29 | Maintains | Buy |
03/10/2023 | 297.66% | Credit Suisse | $38 → $34 | Maintains | Outperform |
03/10/2023 | 250.88% | HC Wainwright & Co. | $65 → $30 | Maintains | Buy |
11/09/2022 | 660.23% | HC Wainwright & Co. | $80 → $65 | Maintains | Buy |
08/09/2022 | 344.44% | Credit Suisse | $43 → $38 | Maintains | Outperform |
06/06/2022 | 87.13% | Stifel | $35 → $16 | Maintains | Buy |
05/19/2022 | 461.4% | Piper Sandler | $70 → $48 | Maintains | Overweight |
03/01/2022 | 321.05% | Stifel | $60 → $36 | Maintains | Buy |
12/22/2021 | 192.4% | Jefferies | $65 → $25 | Downgrades | Buy → Hold |
09/30/2021 | 1139.77% | Stifel | → $106 | Initiates Coverage On | → Buy |
04/06/2021 | 1022.81% | UBS | → $96 | Initiates Coverage On | → Buy |
02/11/2021 | 1046.2% | Credit Suisse | $62 → $98 | Maintains | Outperform |
02/10/2021 | 1069.59% | HC Wainwright & Co. | → $100 | Initiates Coverage On | → Buy |
08/11/2020 | 648.54% | Cantor Fitzgerald | → $64 | Initiates Coverage On | → Overweight |
08/11/2020 | 543.27% | Piper Sandler | → $55 | Initiates Coverage On | → Overweight |
08/11/2020 | 484.8% | Jefferies | → $50 | Initiates Coverage On | → Buy |
08/11/2020 | 519.88% | Credit Suisse | → $53 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/14/2023 | 16.96% | Stifel | 11 美元 → 10 美元 | 維護 | 買 |
2023 年 11 月 10 日 | 28.65% | 派珀·桑德勒 | 8 美元 → 11 美元 | 維護 | 超重 |
2023 年 4 月 10 日 | 215.79% | 瑞銀(UBS) | 29 美元 → 27 美元 | 維護 | 買 |
2023 年 4 月 10 日 | 169.01% | 坎託·菲茨傑拉德 | 18 美元 → 23 美元 | 維護 | 超重 |
2023 年 3 月 10 日 | 104.68% | HC Wainwright & Co. | 16 美元 → 17.5 美元 | 重申 | 購買 → 購買 |
09/12/2023 | 110.53% | 坎託·菲茨傑拉德 | → 18 美元 | 重申 | 超重 → 超重 |
09/07/2023 | 110.53% | 坎託·菲茨傑拉德 | → 18 美元 | 恢復 | 超重 → 超重 |
08/14/2023 | 110.53% | 坎託·菲茨傑拉德 | 22 美元 → 18 美元 | 維護 | 超重 |
08/11/2023 | 110.53% | 坎託·菲茨傑拉德 | 22 美元 → 18 美元 | 維護 | 超重 |
08/11/2023 | -6.43% | 派珀·桑德勒 | 48 美元 → 8 美元 | 維護 | 超重 |
08/11/2023 | 87.13% | HC Wainwright & Co. | 30 美元 → 16 美元 | 維護 | 買 |
2023 年 7 月 24 日 | 157.31% | 坎託·菲茨傑拉德 | → 22 美元 | 重申 | 超重 → 超重 |
05/12/2023 | 250.88% | HC Wainwright & Co. | → 30 美元 | 重申 | 購買 → 購買 |
03/15/2023 | 239.18% | 瑞銀(UBS) | 31 美元 → 29 美元 | 維護 | 買 |
03/10/2023 | 297.66% | 瑞士信貸 | 38 美元 → 34 美元 | 維護 | 跑贏大盤 |
03/10/2023 | 250.88% | HC Wainwright & Co. | 65 美元 → 30 美元 | 維護 | 買 |
11/09/2022 | 660.23% | HC Wainwright & Co. | 80 美元 → 65 美元 | 維護 | 買 |
08/09/2022 | 344.44% | 瑞士信貸 | 43 美元 → 38 美元 | 維護 | 跑贏大盤 |
2022 年 6 月 6 日 | 87.13% | Stifel | 35 美元 → 16 美元 | 維護 | 買 |
05/19/2022 | 461.4% | 派珀·桑德勒 | 70 美元 → 48 美元 | 維護 | 超重 |
03/01/2022 | 321.05% | Stifel | 60 美元 → 36 美元 | 維護 | 買 |
12/22/2021 | 192.4% | 傑富瑞集團 | 65 美元 → 25 美元 | 降級 | 買入 → 持有 |
09/30/2021 | 1139.77% | Stifel | → 106 美元 | 啓動覆蓋範圍開啓 | → 購買 |
04/06/2021 | 1022.81% | 瑞銀(UBS) | → 96 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2021 年 11 月 2 日 | 1046.2% | 瑞士信貸 | 62 美元 → 98 美元 | 維護 | 跑贏大盤 |
2021 年 10 月 2 日 | 1069.59% | HC Wainwright & Co. | → 100 美元 | 啓動覆蓋範圍開啓 | → 購買 |
08/11/2020 | 648.54% | 坎託·菲茨傑拉德 | → 64 美元 | 啓動覆蓋範圍開啓 | → 超重 |
08/11/2020 | 543.27% | 派珀·桑德勒 | → 55 美元 | 啓動覆蓋範圍開啓 | → 超重 |
08/11/2020 | 484.8% | 傑富瑞集團 | → 50 美元 | 啓動覆蓋範圍開啓 | → 購買 |
08/11/2020 | 519.88% | 瑞士信貸 | → 53 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for ALX Oncology Holdings (ALXO)?
ALX Oncology Holdings(ALXO)的目標價格是多少?
The latest price target for ALX Oncology Holdings (NASDAQ: ALXO) was reported by Stifel on November 14, 2023. The analyst firm set a price target for $10.00 expecting ALXO to rise to within 12 months (a possible 16.96% upside). 16 analyst firms have reported ratings in the last year.
Stifel於2023年11月14日公佈了ALX腫瘤控股公司(納斯達克股票代碼:ALXO)的最新目標股價。該分析公司將目標股價定爲10.00美元,預計ALXO將在12個月內升至12個月內(可能上漲16.96%)。去年有16家分析公司公佈了評級。
What is the most recent analyst rating for ALX Oncology Holdings (ALXO)?
ALX Oncology Holdings(ALXO)的最新分析師評級是多少?
The latest analyst rating for ALX Oncology Holdings (NASDAQ: ALXO) was provided by Stifel, and ALX Oncology Holdings maintained their buy rating.
Stifel對ALX Oncology Holdings(納斯達克股票代碼:ALXO)的最新分析師評級由Stifel提供,ALX Oncology Holdings維持買入評級。
When is the next analyst rating going to be posted or updated for ALX Oncology Holdings (ALXO)?
ALX Oncology Holdings(ALXO)的下一份分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與ALX Oncology Holdings的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。ALX Oncology Holdings的最新評級是在2023年11月14日公佈的,因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating ALX Oncology Holdings (ALXO) correct?
分析師對ALX Oncology Holdings(ALXO)的評級正確嗎?
While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a maintained with a price target of $11.00 to $10.00. The current price ALX Oncology Holdings (ALXO) is trading at is $8.55, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的ALX腫瘤學控股公司(ALXO)評級保持不變,目標股價爲11.00美元至10.00美元。ALX Oncology Holdings(ALXO)目前的交易價格爲8.55美元,超出了分析師的預期區間。